Excess body weight at diagnosis is associated with inferior ALL outcomes in male adolescents in the ALL-BFM 2000 study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Body weight at diagnosis may influence outcomes in childhood acute lymphoblastic leukemia (ALL), although current evidence remains conflicting. Both, underweight and overweight/obesity at diagnosis can negatively affect outcomes. Here, we present data from the ALL-BFM 2000 trial on excess body weight at diagnosis and inferior outcome, especially among male patients aged ≥10 years with ALL. We analyzed 3920 patients with B-cell precursor (BCP)-ALL and 674 patients with T-cell ALL (T-ALL), aged 1 to 17 years. Outcome was assessed by weight category (underweight, normal weight, and overweight/obesity) and sex, age, or risk group. We found that patients aged ≥10 years who were overweight/obese at diagnosis had a significantly worse event-free survival (EFS; BCP-ALL, 63.6%; T-ALL, 65.8%) than patients with normal weight (BCP-ALL, 77.8%; T-ALL, 81.2%) or those who were underweight (BCP-ALL, 77.9%; T-ALL, 83.8%). Interestingly, sex critically determined outcome in patients ≥10 years because especially male patients with overweight/obesity at diagnosis experienced a significantly shorter EFS (BCP-ALL, 54.9%; T-ALL, 62.7%) than patients with normal weight (BCP-ALL, 81.9%; T-ALL, 78.3%) of this age group. Overweight/obesity at diagnosis was identified as independent negative prognostic marker in the group of male (hazard ratio [HR], 2.23) but not female (HR, 1.04) patients ≥10 years with ALL. Male patients ≥10 years with overweight/obesity classified as medium risk or high risk by minimal residual disease showed a higher cumulative incidence of relapse or death, respectively. Our findings suggest that male patients aged ≥10 years with overweight/obesity represent a particularly vulnerable group of patients with ALL who are at increased risk of relapse or death. This trial was registered at www.clinicaltrials.gov as NCT00430118.